Your browser doesn't support javascript.
loading
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao, Yuanyuan; Zhao, Bing; Chen, Gang; Chen, Yinlan; Liao, Zijun; Zhang, Haiming; Feng, Weineng; Li, Yinyin; Weng, Heng; Li, Weidong; Zhou, Yuefen; Ren, Biyong; Lu, Yanda; Chen, Jianhua; Liu, Zhenteng; Su, Zhenzhong; Wang, Wenliang; Zhang, Li.
  • Zhao Y; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
  • Zhao B; Department of Day Ward, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, P. R. China.
  • Chen G; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
  • Chen Y; Department of Medical Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.
  • Liao Z; Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, P. R. China.
  • Zhang H; Department of Medical Oncology, The First People Hospital of Xiangtan, Xiangtan, Hunan, P. R. China.
  • Feng W; Department of Medical Oncology, The First People Hospital of Foshan, Foshan, Guangdong, P. R. China.
  • Li Y; Department of Medical Oncology, Shenyang Tenth People's Hospital, Shenyang, Liaoning, P. R. China.
  • Weng H; Respiratory Medicine, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, Fujian, P. R. China.
  • Li W; Department of Medical Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.
  • Zhou Y; Department of Medical Oncology, The Central Hospital of Lishui, Lishui, Zhejiang, P. R. China.
  • Ren B; Department of Medical Oncology, Chongqing Three Gorges Central Hospital, Chongqing, P. R. China.
  • Lu Y; Department of Medical Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, P. R. China.
  • Chen J; Department of Medical Oncology, Hunan Province Tumor Hospital, Changsha, Hunan, P. R. China.
  • Liu Z; Institute of Materia Medica, Luoxin Pharmaceutical Group Co., Ltd, Shanghai, P. R. China.
  • Su Z; Institute of Materia Medica, Luoxin Pharmaceutical Group Co., Ltd, Shanghai, P. R. China.
  • Wang W; Institute of Materia Medica, Luoxin Pharmaceutical Group Co., Ltd, Shanghai, P. R. China.
  • Zhang L; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
Cancer Commun (Lond) ; 43(2): 246-256, 2023 02.
Article en En | MEDLINE | ID: mdl-36545810
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antieméticos / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antieméticos / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article